Citations

Clear

47 citation(s) found for "Scott, Luis".

Z-coded social determinants of health and cardiovascular risk among patients receiving dialysis
Alhammouri, Hashim, Ibrahim, Ramzi , AlAsmar, Rahmeh, Dreher, Luke, Almakadma, Abdul Hakim , Pham, Hoang Nhat, Mahmoud, Ahmed K, Awad, K, Abdelnabi, Mahmoud, Salih, Mohammed, Agarwal, Siddharth, Al‐Kindi, Sadeer , Sorajja, Dan , Scott, Luis R, Ayoub, C A, Arsanjani, R A, Awad, Kamal , Al-Kindi, Sadeer , Sorajja, Dan , Ayoub, Chadi , Ibrahim, Ramzi , Al-Asmar, Rahmeh , Dreher, Luke , Pham, Hoang Nhat , Awad, Kamal , Abdelnabi, Mahmoud , Agarwal, Siddharth , Hommos, Musab S. , Arsanjani, Reza

Mayo Clinic

Journal of Nephrology | January 6, 2026 | Volume: 39 | Issue: 3 | Pages: 528-535

10.1093/joneph/aajaf060 | PMID 42189835 Get It

Abstract Introduction Cardiovascular disease (CVD) is the leading cause of death among patients with kidney failure on dialysis. Social determinants of health may worsen this risk but are seldom incorporated into prognostic models. ICD-10 Z-codes provide standardized documentation of social determinants of health, yet their prognostic value in dialysis populations remains uncertain. This study examined whether Z-coded social determinants of health are associated with adverse cardiovascular outcomes and mortality among patients receiving dialysis for kidney failure. Methods A retrospective cohort study was conducted using the TriNetX Research Network (2010–2024), encompassing de-identified data from 103 institutions. Adults with kidney failure on chronic dialysis were stratified by the presence of ICD-10 Z-codes (Z55–Z65). Propensity score matching (1:1) balanced demographics, comorbidities, medications, and laboratory values. Primary outcomes were all-cause mortality and hospitalization; secondary outcomes included acute heart failure, myocardial infarction, stroke, cardiac arrest, bradyarrhythmias, and ventricular tachycardia. Results After matching, mean age was 62 years, and 42.4% were female in the Z-code cohort versus 41.2% in controls. Over one year, mortality occurred in 12.5% versus 10.9% (hazard ratio [HR], 1.22; 95% confidence interval [CI], 1.15–1.29) and all-cause hospitalizations in 57.3% versus 53.1% (HR, 1.22; 95% CI, 1.19–1.26). Cardiovascular complications were consistently higher in Z-coded patients, including heart failure (24.3% vs 20.5%; HR, 1.29), myocardial infarction (8.0% vs 7.1%; HR, 1.19), stroke (6.6% vs 6.2%; HR, 1.13), cardiac arrest (3.8% vs 3.1%; HR, 1.29), and bradyarrhythmias (6.9% vs 5.5%; HR, 1.33). Discussion Among patients with kidney failure, documented Z-coded social risk factors were associated with greater mortality and cardiovascular morbidity. Incorporating social determinants of health documentation into nephrology care may improve risk stratification and inform targeted interventions.
Propensity‐Matched Five‐Year Cardiac Resynchronization Therapy Outcomes in Sarcoidosis With Heart Failure
Yeo, Yong Hao , Ong, Tze Ern , Tan, Min Choon , Vigneswaramoorthy, Nishanthi, Scott, Luis R. , Masry, Hicham El , Sorajja, Dan , Deshmukh, Abhishek , DeSimone, Christopher V. , Lee, Justin Z. , Tan, Min C , El Masry, Hicham , Deshmukh, Abhishek J , DeSimone, Christopher V , Yeo, Yong Hao , Vignarajah, Aravinthan

Mayo Clinic

Journal of Cardiovascular Electrophysiology | November 25, 2025 | Volume: 37 | Issue: 1 | Pages: 119-125

10.1111/jce.70204 | PMID 41286588 Get It

ABSTRACT Introduction Cardiac resynchronization therapy (CRT) improves clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, data on its efficacy in patients with sarcoidosis and HFrEF are limited. Methods Using the TriNetX network, we identified patients with sarcoidosis, heart failure with a left ventricular ejection fraction (LVEF) below 35%, and either left bundle branch block (LBBB) or prolonged QRS duration ( > 150 ms) between 2014 and 2019. Patients were categorized into two cohorts: (1) those who received CRT and (2) those who received an ICD‐only implant. Five‐year outcomes included all‐cause mortality, all‐cause hospitalization, heart failure exacerbation, and the proportion of patients with improvement in LVEF to greater than 40% and greater than 50%. Results Out of 245 eligible patients, we identified a cohort of 87 patients (mean age 62.6 ± 9.5 years) who received CRT and 87 patients (mean age 62.1 ± 11.1 years) who received ICD‐only implant, with similar propensity scores, and included them in a comparative analysis. At 5‐year follow‐up, the CRT group demonstrated outcomes comparable to the ICD‐only implant group for all‐cause mortality (14.9% vs. 20.7%; HR 0.63; 95% CI 0.31–1.28; p = 0.19), all‐cause hospitalization (83.9% vs. 77.0%; HR 1.24; 95% CI 0.89–1.73; p = 0.19), and heart failure exacerbation (28.7% vs. 28.7%; HR 0.90; 95% CI 0.52–1.57; p = 0.72). The proportion of patients with improvement in LVEF to greater than 40% and greater than 50% was also similar in both groups (LVEF > 40%, 43.7% vs. 33.3%; HR 1.30; 95% CI 0.80–2.10; p = 0.29; LVEF > 50%, 31.0% vs. 17.2%; HR 1.72; 95% CI 0.92–3.24; p = 0.09). Conclusion CRT implantation had similar long‐term outcomes compared to ICD‐only implantation in patients with sarcoidosis and HFrEF, particularly all‐cause mortality, all‐cause hospitalization, heart failure exacerbation, and the proportion of patients with improvement in LVEF to greater than 40% and greater than 50%.
Response to Letter Regarding “Sodium–Glucose Cotransporter‐2 Inhibitors and Stroke Risk in Patients With Atrial Fibrillation”
Mee, Xuan Ci , Ibrahim, Ramzi , Lim, Ghee Kheng, Abdelnabi, Mahmoud , Habib, Eiad , Lee, Justin Z. , Lester, Steven J., Scott, Luis R. , Sorajja, Dan , Ayoub, Chadi , Mee, Xuan Ci , Ibrahim, Ramzi , Ibrahim, Ramzi , Lim, Ghee Kheng, Pham, Hoang Nhat , Farina, Juan M. , Lee, Kwan , Arsanjani, Reza

Mayo Clinic

Journal of Cardiovascular Electrophysiology | November 19, 2025 | Volume: 37 | Issue: 1 | Pages: 216-217

10.1111/jce.70189 | PMID 41255042 Get It

Response to Letter to the Editor Concerning the Article “Sodium‐Glucose Cotransporter‐2 Inhibitors and Stroke Risk in Patients With Atrial Fibrillation”
Ibrahim, Ramzi , Lim, Ghee K., Mee, Xuan Ci , Abdelnabi, Mahmoud , Habib, Eiad , Lee, Justin Z. , Lester, Steven J., Scott, Luis R. , Sorajja, Dan , Ayoub, Chadi , Pham, Hoang N, Mee, Xuan Ci , Ibrahim, Ramzi , Ibrahim, Ramzi , Lim, Ghee K., Pham, Hoang N., Farina, Juan M. , Lee, Kwan , Arsanjani, Reza

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 25, 2025 | Volume: 36 | Issue: 8 | Pages: 2105-2106

10.1111/jce.70030 | PMID 40709569 Get It

Sodium‐Glucose Cotransporter‐2 Inhibitors and Stroke Risk in Patients With Atrial Fibrillation
Lim, Ghee Kheng, Mee, Xuan Ci , Abdelnabi, Mahmoud , Habib, Eiad , Lee, Justin Z. , Lester, Steven J., Scott, Luis, Sorajja, Dan , Mee, Xuan Ci , Lim, Ghee Kheng, Ibrahim, Ramzi , Pham, Hoang Nhat , Farina, Juan M. , Lee, Kwan , Arsanjani, Reza

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 13, 2025 | Volume: 36 | Issue: 8 | Pages: 1826-1835

10.1111/jce.16739 | PMID 40509618 Get It

ABSTRACT Background Sodium‐glucose cotransporter 2 inhibitors (SGLT2‐Is) are primarily used to manage type 2 diabetes mellitus (T2DM) and heart failure (HF), but their impact on reducing stroke risk in patients with atrial fibrillation (AF) remains underexplored. We aimed to investigate the impact of SGLT2‐Is for stroke risk mitigation in patients with AF. Methods Using the TriNetX database, we performed a retrospective cohort study on patients ≥ 18 years with AF and on anticoagulation. These patients were then classified into two cohorts based on their use of SGLT2‐Is. To balance the baseline demographics, comorbidities, and medication use, propensity score matching (PSM) was used. The primary outcome was ischemic and hemorrhagic strokes, and the secondary outcomes were all‐cause mortality, all‐cause hospitalizations, need for AF cardioversion or antiarrhythmic drug initiation, and cardiac arrest. Adjusted odds ratio (aORs) and hazard ratios (HRs) were estimated for both the primary and secondary outcomes. Results A total of 152,778 patients with 76,389 patients were included in each cohort (SGLT2‐Is users, and non‐users) after PSM. The mean age of both SGLT2‐Is users and non‐users was 72.8 years. For the SGLT2‐Is users, the mean follow‐up period was 317 days, whereas the mean follow‐up period for the non‐users was 306 days. For the primary outcome, we found that SGLT2‐Is users had a lower risk of ischemic stroke (aOR: 0.889; 95% CI: 0.857–0.923) and hemorrhagic stroke (aOR: 0.682; 95% CI: 0.620–0.749) compared to non‐users. Regarding the secondary outcomes, SGLT2‐Is users also had lower risk for all‐cause mortality (aOR: 0.615; 95% CI: 0.595–0.636), all‐cause hospitalizations (aOR: 0.599; 95% CI: 0.587–0.611), need of AF cardioversion (aOR: 0.846; 95% CI: 0.813–0.881), antiarrhythmic drug initiation (aOR: 0.790; 95% CI: 0.766–0.815), and cardiac arrest (aOR: 0.643; 95% CI: 0.601–0.688). Conclusions SGLT2‐I use in patients with AF is associated with lower risks of stroke and other cardiovascular and non‐cardiovascular outcomes. Future prospective research is needed to validate these findings.
Exploring the effects of glucagon-like peptide-1 receptor agonists on ventricular arrhythmias: a propensity score-matched analysis
Tan, Min Choon , Vignarajah, Aravinthan , Yeo, Yong Hao , Lee, Justin Z. , Russo, Andrea M. , Scott, Luis R. , Sorajja, Dan , Yeo, Yong Hao , Tan, Min C

Mayo Clinic

Europace | May 2, 2025 | Volume: 27 | Issue: 5 | Pages: No page available

10.1093/europace/euaf090 | PMID 40314211 Get It

Late Sustained Ventricular Arrhythmias After Left Ventricular Assist Device Implantation: Outcomes and Predictors
Karikalan, Suganya Arunachalam , Lee, Justin Z. , Zhang, Nan , Killu, Ammar M. , Deshmukh, Abhishek , Sorajja, Dan , El‐Masry, Hicham, Mulpuru, Siva K. , Cha, Yong‐Mei , Scott, Luis, Masry, Hicham El , Karikalan, Suganya , Tan, Min Choon , Killu, Ammar M , El-Masry, Hicham, Cha, Yong-Mei , El Masry, Hicham , McLeod, Christopher J.

Mayo Clinic

Pacing and Clinical Electrophysiology | February 11, 2025 | Volume: 48 | Issue: 4 | Pages: 386-393

10.1111/pace.15158 | PMID 39925318 Get It

ABSTRACTBackgroundThe factors contributing to sustained ventricular arrhythmias (VAs) >30 days after left ventricular assist device (LVAD) implantation are not well‐established.ObjectivesThis study aimed to predict the factors associated with late sustained VAs after LVAD implantation and develop a predictive score to identify patients with an increased risk of late sustained VAs after the procedure.MethodsWe performed a retrospective cohort study on a training cohort of 623 patients and a validation cohort of 157 patients who underwent LVAD implantation at the Mayo Clinic (Rochester, Phoenix, and Jacksonville) from January 1, 2000, to December 30, 2020. Late sustained VAs were defined as ventricular tachycardia (VT) and ventricular fibrillation (VF) occurring >30 days after the LVAD procedure. Detailed chart reviews of the electronic health records within the Mayo Clinic and outside medical records were performed.ResultsA total of 780 patients were included in our study. Late sustained VAs occurred in 30% (n = 232) of the patients. The significant factors associated with late sustained VAs after LVAD were the history of VAs prior to LVAD (34.1% vs. 23.0%, p < 0.01), implantable cardiac defibrillator (ICD) (87.9% vs. 77.6%, p < 0.01) or cardiac resynchronization therapy (CRT) in situ (43.5% vs. 33.6%, p = 0.008), VT ablation prior to LVAD (5.2% vs. 1.8%, p = 0.010), use of amiodarone (49.1% vs. 38.7%, p = 0.007), use of mexiletine (15.5% vs. 5.7%, p < 0.01), and higher left ventricular end‐diastolic diameter (LVEDD) on echocardiography prior to LVAD implantation (71.4 vs. 68.7 mm, p = 0.002). During follow‐up, the patients who developed late sustained VAs after LVAD had lower survival than those who did not (HR = 1.96, 95% CI:156–2.4, p < 0.001). The average time from LVAD to orthotopic heart transplant was longer among late sustained VAs patients (23 vs. 14 months, p < 0.01). The “VIN” risk score was created to identify four risk groups: low (scores 0), intermediate (score 1), high (score 2), and very high (score 3). The rates of late VA's in the training cohort at 1 year were 9.5%, 14%, 18%, and 25% which was almost similar to the risk of late VA's at validation cohort 10%, 12%, 20%, and 63%, respectively.ConclusionsLate sustained VAs occurred in 30% of the patients who received LVAD and were associated with lower survival. The VIN risk score was developed and validated to stratify patients into low, intermediate, high, and very high risk of late sustained VAs.
Elevated lipoprotein(a) levels linked to new-onset atrial fibrillation: insights from a retrospective cohort study
Kamel, Moaz, Mahmoud, Ahmed , Badr, Amro , Pereyra, Milagros , Scalia, Isabel G. , Ali, Nima Baba , Alsidawi, Said , Lester, Steven J., Rmilah, Anan Abu, Barry, Timothy, Shen, Win K., Scott, Luis R. , Masry, Hicham El , Valverde, Arturo M. , Sorajja, Dan , Ayoub, Chadi , Arsanjani, Reza , Mahmoud, Ahmed K , Pereyra Pietri, Milagros, Alsidawi, Said , Sardana, Mayank , Sorajja, Dan , Ayoub, Chadi , Arsanjani, Reza , El Masry, Hicham , Pereyra, Milagros , Scalia, Isabel G , Awad, Kamal , Farina, Juan M. , Abbas, Mohammed Tiseer , Rmilah, Anan Abu , Srivathsan, Komandoor

Mayo Clinic

European Journal of Preventive Cardiology | February 7, 2025 | Volume: 32 | Issue: 9 | Pages: 769-777

10.1093/eurjpc/zwaf063 | PMID 39919039 Get It

Abstract Aims Atrial fibrillation (AF) is the most common cardiac arrhythmia. Although lipoprotein(a) [Lp(a)] is known to be a well-established risk factor for atherosclerotic cardiovascular disease, its role in the development of AF, independent of this association, remains unclear. Methods and results Adult patients from the three Mayo Clinic sites with a baseline Lp(a) and without AF history were included. Patients were categorized into two groups based on their Lp(a) levels: high Lp(a) (≥50 mg/dL) and low Lp(a) (&lt;50 mg/dL). Survival probabilities free from incident AF were compared between Lp(a) groups, during a follow-up period up to 15 years, using the Kaplan–Meier curve and the log-rank test. Multivariable Cox regression analysis was also conducted. A total of 75 376 patients were included (median age: 55 years, 59% males), with a median follow-up duration of 8.8 (inter-quartile range: 3.4, 14.8) years. Incident AF was detected in 5738 (7.6%) patients. Survival probability free from incident AF was significantly lower in patients with elevated Lp(a) (86%) compared with those with low Lp(a) (88%, log-rank P &lt; 0.001). Multivariable analysis adjusted for potential risk factors of AF showed a statistically significant association of elevated Lp(a) with an 11% increase in AF risk (adjusted hazard ratio: 1.11, 95% confidence interval: 1.05–1.18). Conclusion Our study suggests that elevated Lp(a) (≥50 mg/dL) is an independent risk factor for incident AF. Future prospective studies are warranted to validate our results and to test if reducing Lp(a) could mitigate the burden of AF.
Abstract 4141974: Impact of Timing of Pacemaker Reimplantation Following Transvenous Lead Removal of Infected Cardiac Implantable Electronic Devices on Hospital Outcomes
Ang, Qi Xuan , Sorajja, Dan , Scott, Luis R. , Cha, Yong‐Mei , Russo, Andrea M. , Lee, Justin Z. , Tan, Min Choon , Yeo, Yong Hao , Rattanawong, Pattara

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4141974 Get It

Background: The optimal timing of pacemaker reimplantation following transvenous lead removal (TLR) of infected cardiac implantable electronic device (CIED) remains unclear. Objective: Our study aimed to assess the impact of timing to pacemaker reimplantation after TLR of infected CIED on hospital outcomes. Method: Using the Nationwide Readmissions Database, patients aged ≥18 years who underwent new pacemaker implantation with percutaneous approach following TLR of infected CIED from 2017 to 2020 were identified. The study population was stratified based on the timing of pacemaker reimplantation following TLR of infected CIED: early (<5 days) vs delayed (≥5 days). Weighted-propensity-score matched conditional multivariable logistic regressions were performed to determine the impact of the timing on various outcomes. Results: In our study, 469 (66.9%) patients received early device reimplantation, and 232 (33.1%) patients received delayed device reimplantation (≥5 days). Post-procedurally, patients in the delayed group had a higher risk of prolonged hospital stay (95% CI OR: 42.37 (6.36 – 282.11); p<0.01) and non-home discharge (95% CI OR: 2.00 (1.35 – 2.95), p<0.01). There was no significant difference between both groups in the early mortality, 30-day readmission, and procedural complications. Conclusion: Our study suggests that time-to-device reimplantation from TLR of infected CIED did not affect the overall short-term in-hospital outcomes. However, delayed device reimplantation was associated with a higher rate of prolonged hospital stay and non-home discharge.
Electrical storm after left ventricular assist device (LVAD) implantation
Karikalan, Suganya Arunachalam , Zhang, Nan , Masry, Hicham El , Killu, Ammar M. , DeSimone, Christopher V. , Deshmukh, Abhishek , Sorajja, Dan , Scott, Luis R. , Cha, Yong‐Mei , Lee, Justin Z. , Karikalan, Suganya , Tan, Min Choon , El Masry, Hicham , Killu, Ammar M , DeSimone, Christopher V , Deshmukh, Abhishek J , Cha, Yong-Mei , McLeod, Christopher J. , Srivathsan, Komandoor

Mayo Clinic

Journal of Cardiovascular Electrophysiology | April 9, 2024 | Volume: 35 | Issue: 6 | Pages: 1196-1202

10.1111/jce.16275 | PMID 38590268 Get It

AbstractIntroductionVentricular tachycardia storm or electrical storm (ES) is a common complication following left ventricular assist device (LVAD) implantation. The factors contributing to ES and outcomes are less studied. The study aimed to determine the factors associated with ES and the probability of survival in patients undergoing LVAD in three tertiary centers over a span of 15 years.MethodsWe performed a retrospective cohort study on all patients who underwent LVAD implantation at the Mayo Clinic (Rochester, Phoenix, and Jacksonville) from January 1, 2006 to December 31, 2020. ES was defined as ≥3 episodes of sustained ventricular tachycardia over a period of 24 h with no identifiable reversible cause. Detailed chart reviews of the electronic health records within the Mayo Clinic and outside medical records were performed.ResultsA total of 883 patients who underwent LVAD implantation were included in our study. ES occurred in 7% (n = 61) of patients with a median of 13 days (interquartile range [IQR]: 5–297 days) following surgery. We found 57% of patients (n = 35) developed ES within 30 days, while 43% (n = 26) patients developed ES at a median of 545 (IQR 152–1032) days after surgery. Following ES, 26% of patients died within 1 year. Patients with ES had a significant association with a history of ventricular arrhythmias and implantable cardioverter defibrillator (ICD) shocks before the procedure. ES was significantly associated with reduced survival compared to patients without ES (hazards ratio [HR]: 1.92, 95% CI: 1.39–2.64, p < .001).ConclusionFollowing LVAD implantation, the rate of ES was 7% with majority of ES occurring within 30 days of LVAD. Risk factors for ES included pre‐implant history of ventricular arrhythmias and ICD shock. ES was significantly associated with reduced survival compared to patients without ES.